Editas Medicine, Inc. (EDIT)
- Previous Close
1.3800 - Open
1.4000 - Bid 1.3600 x 400
- Ask 1.4300 x 600
- Day's Range
1.3600 - 1.4300 - 52 Week Range
0.9100 - 6.2200 - Volume
965,550 - Avg. Volume
3,651,114 - Market Cap (intraday)
116.779M - Beta (5Y Monthly) 2.15
- PE Ratio (TTM)
-- - EPS (TTM)
-3.0400 - Earnings Date Aug 5, 2025 - Aug 11, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.38
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
www.editasmedicine.comRecent News: EDIT
View MorePerformance Overview: EDIT
Trailing total returns as of 5/15/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EDIT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EDIT
View MoreValuation Measures
Market Cap
116.78M
Enterprise Value
-73.05M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.22
Price/Book (mrq)
1.87
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-36.80%
Return on Equity (ttm)
-140.82%
Revenue (ttm)
35.84M
Net Income Avi to Common (ttm)
-251.23M
Diluted EPS (ttm)
-3.0400
Balance Sheet and Cash Flow
Total Cash (mrq)
220.96M
Total Debt/Equity (mrq)
49.88%
Levered Free Cash Flow (ttm)
-103.52M